Lilly among those eyeing antibiotic maker Cubist, analyst says

Back to TopCommentsE-mailPrintBookmark and Share

The timing may be right for a takeover of Cubist Pharmaceuticals Inc.

The rising threat from drug-resistant germs and increasing calls from global health groups for more potent antibiotics is placing a premium on companies such as Cubist. The $4.8 billion drug developer is preparing to introduce four new medicines by 2020 to combat bacterial infections that have become resistant to older therapies because of decades of overuse.

Cubist may receive takeover offers based on the prospects for those remedies and could get sold for about 50 percent more than its current price, Cowen Group Inc. said. It already has one blockbuster drug on the market, and analysts estimate its revenue will double to almost $2 billion by 2018.

Pfizer Inc. could fold Cubist’s antibiotics sales force into its acute-care division, while new legislative efforts to revive the antibiotic market also could draw Eli Lilly and Co. or Johnson & Johnson to the bidding table, according to Robert W. Baird & Co.

Lexington, Massachusetts-based Cubist “would be pretty accretive to any company who would be looking to buy them,” Brian Skorney, a New York-based analyst at Baird, said. “They have a drug that’s selling $1 billion a year in the U.S. That’s always an attractive asset.”

If the new drugs “are as successful as management’s contention is, the valuation would see a significant step up and any M&A premium would see a similar step up,” he said.

Julie DiCarlo, a spokeswoman for  based Cubist, declined to comment. Representatives for Indianapolis-based Lilly, J&J and New York-based Pfizer declined to comment.

Drug companies had largely abandoned antibiotics to focus on more profitable chronic illnesses, such as diabetes and heart disease. Now that traditional antibiotics are becoming ineffective, there’s growing unmet demand. It means that common infections and minor injuries could end up being deadly, according to the World Health Organization.

The U.S. Centers for Disease Control and Prevention said antibiotic resistance is killing at least 23,000 Americans a year, making it “one of our most serious health threats.”

Incentive program

President Barack Obama enacted the Generating Antibiotic Incentives Now, or GAIN Act, in 2012 to encourage drugmakers to invest in new antibiotics by lengthening the time they get to sell the treatment exclusively before facing competition from cheaper generic versions.

The GAIN Act may entice companies that don’t have an existing antibiotics business to make bids for Cubist to enter the market, said David Krempa, a Chicago-based analyst at Morningstar Inc. It might be enough to get Lilly or New Brunswick, New Jersey-based J&J “back in the game,” Skorney of Baird said.

“It’s not like it’s a small company where the only people it would make sense for it to be bought by are people that already have the presence there and can buy and cut out the sales force,” Krempa said. “Cubist is big enough that if someone were looking to get into that market that could be one way to get in.”

Cubist would also be a cheap takeover candidate, making a deal even more compelling, he said.

The drug developer was valued last week at 2.4 times analysts’ average revenue estimate for 2018. That’s a lower valuation than 86 percent of U.S. pharmaceutical and biotechnology companies larger than $1 billion, according to data compiled by Bloomberg.

Less risk

Cubist’s Cubicin, a daily injection to treat Methicillin-resistant Staphylococcus Aureus, or MRSA, is what the pharmaceutical industry calls a blockbuster drug because it generates more than $1 billion in annual revenue. That makes Cubist a less risky target than a biotechnology company that doesn’t yet have any approved or marketed medicines, said Alan Carr, an analyst at Needham & Co.

“Acquirers have tended to be risk-averse and have looked for later stage assets when they’re acquiring something,” Carr said. “They’d rather pay more for a de- risked asset rather than invest in something early stage that has a lot of risk embedded in it.”

For companies that still have at least a small sales team dedicated to antibiotics like Cubicin, Cubist would be a relatively easy company to acquire, according to Irina Rivkind, a New York-based analyst with Cantor Fitzgerald.

Pfizer’s best-selling antibiotic—Zyvox, for MRSA—generated $1.35 billion of sales last year and will begin facing generic competition in the second quarter of 2015. An easy way for Pfizer to maintain its anti-infective revenue would be to acquire a company such as Cubist, Rivkind said in an e-mail.

“It can generate cost synergies by acquiring Cubist and stripping out its sales force and research expenditures,” she said.

There have been a flurry of mergers and acquisitions in the health-care industry this year, driven by growth-hungry acquirers seeking to take advantage of low interest rates and also reduce their taxes. The record $320 billion of transactions through last week is already double the volume for all of last year, according to data compiled by Bloomberg.

A drugmaker might pay $95 a share for Cubist, representing a 50-percent premium to last week’s closing price, according to the average of three analysts’ estimates. That would value the company at more than $7 billion. Skorney said that could be a problem for Cubist’s management, who may value the company’s antibiotic pipeline much higher.

New drugs

Cubist has applied for U.S. Food and Drug Administration approval for ceftolozane/tazobactam, an antibiotic for complicated urinary tract infections. If the drug is approved, which could happen as early as December, a buyer that has both U.S. and international hospital-based sales teams would be drawn to the asset, Ken Cacciatore, a New York-based analyst at Cowen, wrote in a July 23 report.

On the other hand, the low profit margins for antibiotics may make Cubist less appealing, Skorney said. Cubist earned less than a penny of profit on each dollar of sales in the past 12 months, versus the 6-cent average for its closest peers, data compiled by Bloomberg show.

“You really have very little pricing power and there’s so many generic options available to treat bacterial infections that the products become very, very niche,” Skorney said.

That may be changing. Biotechnology companies are beginning to demand better prices for their antibiotics, and the growing need for new medicines may position Cubist to profit off this improved pricing power, Morningstar’s Krempa said.

Antibiotics “have life-saving power and yet people are only paying hundreds or a couple thousand dollars for them,” Krempa said. “You should be able to increase prices consistently for a long period of time.”


  • business model
    Big Pharma abandoned antibiotics as a market because the existing (low cost) generics were so effective. And antibiotics actually cure the patient - difficult to make such a product as profitable as products that 'manage' the disease for the patient. Solvadi (Gilead's 99% cure for HCV) is a perfect example of how difficult it is to negotiate pricing that really reflects the value of curing the disease.
  • once again a thriving new Pharma may bite the dust
    So once again, rather than this company being allowed to grow to be equal to Pfizer, Lilly, J&J, they will be swallowed up, probably to lose their capability to invent new products with the huge bureaucracies and business giants that swallow them. The question remains, why didn't Lilly keep developing their own antibiotics, they developed some of the best, abandoned this area, now they are going to buy innovation, invention and new product development and probably squelch this high rising company that could grow to 10-20 billion dollars by focusing in an area that all other Pharmas have abandoned. Amazing how smaller companies have the edge and then are purchased only to have their edge removed by bulky, bureaucratic, noninventive huge corporations.

    Post a comment to this story

    We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
    You are legally responsible for what you post and your anonymity is not guaranteed.
    Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
    No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
    We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

    Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

    Sponsored by

    facebook - twitter on Facebook & Twitter

    Follow on TwitterFollow IBJ on Facebook:
    Follow on TwitterFollow IBJ's Tweets on these topics:
    Subscribe to IBJ
    1. I never thought I'd see the day when a Republican Mayor would lead the charge in attempting to raise every tax we have to pay. Now it's income taxes and property taxes that Ballard wants to increase. And to pay for a pre-K program? Many studies have shown that pre-K offer no long-term educational benefits whatsoever. And Ballard is pitching it as a way of fighting crime? Who is he kidding? It's about government provided day care. It's a shame that we elected a Republican who has turned out to be a huge big spending, big taxing, big borrowing liberal Democrat.

    2. Why do we blame the unions? They did not create the 11 different school districts that are the root of the problem.

    3. I was just watching an AOW race from cleveland in 1997...in addition to the 65K for the race, there were more people in boats watching that race from the lake than were IndyCar fans watching the 2014 IndyCar season finale in the Fontana grandstands. Just sayin...That's some resurgence modern IndyCar has going. Almost profitable, nobody in the grandstands and TV ratings dropping 61% at some tracks in the series. Business model..."CRAZY" as said by a NASCAR track general manager. Yup, this thing is purring like a cat! Sponsors...send them your cash, pronto!!! LOL, not a chance.

    4. I'm sure Indiana is paradise for the wealthy and affluent, but what about the rest of us? Over the last 40 years, conservatives and the business elite have run this country (and state)into the ground. The pendulum will swing back as more moderate voters get tired of Reaganomics and regressive social policies. Add to that the wave of minority voters coming up in the next 10 to 15 years and things will get better. unfortunately we have to suffer through 10 more years of gerrymandered districts and dispropionate representation.

    5. Funny thing....rich people telling poor people how bad the other rich people are wanting to cut benefits/school etc and that they should vote for those rich people that just did it. Just saying..............